Clinical Trial Update: Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

View source ↗

Summary

This Clinical Trial Update reports that a post-marketing surveillance study of mavacamten in Japanese patients with obstructive hypertrophic cardiomyopathy is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM) | Status: RECRUITING